Supplementary Figure S8 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

Key Points

Dynamic changes in PD-L1 combined positive score observed in response to treatment.
Patients with resectable head and neck squamous cell carcinoma received durvalumab alone or with tremelimumab.
Data suggest that both treatments may influence the PD-L1 response in this cancer type.
Highlights potential for these immunotherapies in preoperative settings, warranting further evaluation.

Answers are grounded in this paper and cite their sources.

Open-label trial assesses PD-L1 traits in patients with head and neck squamous cell carcinoma, indicating treatment response.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

Kim et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share